-
13523-5
Apelin-13-5 mg
Price: $576.37List Price: $640.42Endogenous ligand of the APJ receptor, with an EC50 of 0.37 nM acts primarily in the periphery and CNS, playing important roles in regulating cardiovascular function, fluid homeostasis, hypertension, and insulin sensitivity. -
13524-5
Apelin-36-5 mg
Price: $3,521.38List Price: $3,912.65Full-length mature apelin peptide acts primarily in the regulation of cardiovascular function, fluid homeostasis, hypertension, and insulin sensitivity a less potent APJ agonist than either apelin-17 or apelin-13 (EC50 = 20, 2.5, and 0. -
-
-
SML3285-50MG
APIXABAN (C005B-309237)
Price: $673.60List Price: $748.44Biochem/physiol Actions Apixaban is an orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor (human/rabbit Ki = 0.08/0. -
SML3285-10MG
APIXABAN (C005B-309238)
Price: $208.63List Price: $231.81Biochem/physiol Actions Apixaban is an orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor (human/rabbit Ki = 0.08/0. -
15427-1
Apixaban-1 mg
Price: $161.42List Price: $179.36An orally available, selective inhibitor of both free and prothrombinase-bound factor Xa (Ki = 0.8 nM) effective anticoagulant in both preclinical and clinical models of venous and arterial thrombosis. -
15427-10
Apixaban-10 mg
Price: $824.03List Price: $915.59An orally available, selective inhibitor of both free and prothrombinase-bound factor Xa (Ki = 0.8 nM) effective anticoagulant in both preclinical and clinical models of venous and arterial thrombosis. -
15427-50
Apixaban-50 mg
Price: $1,645.73List Price: $1,828.59An orally available, selective inhibitor of both free and prothrombinase-bound factor Xa (Ki = 0.8 nM) effective anticoagulant in both preclinical and clinical models of venous and arterial thrombosis. -
BP546
APRAMYCIN BRITISH PHARMACOPOEIA (BP) RE
Price: $595.01List Price: $661.12This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the -
-